Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

drug- or toxin-induced pulmonary arterial hypertension - Clinical Profile, Genes & Research | Kisho | Kisho

Rare Disease

drug- or toxin-induced pulmonary arterial hypertension

MONDO:0017149

Also known as:drug- or toxin-induced PAH

Overview

Drug- or toxin-induced pulmonary arterial hypertension (PAH) is a form of pulmonary arterial hypertension (PAH) secondary to the exposition to drugs. Drug- or toxin-induced PAH is characterized by elevated pulmonary arterial resistance leading to right heart failure. Drug or toxin induced PAH is progressive and potentially fatal.

Diagnosis

Biomarker and diagnostic research for drug- or toxin-induced pulmonary arterial hypertension has been reported in the published literature.

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

No clinical trials have been registered for drug- or toxin-induced pulmonary arterial hypertension.

202 publications have been identified in PubMed for drug- or toxin-induced pulmonary arterial hypertension. Kisho has analyzed 70 by research type. Research spans Review / Meta-Analysis (89%), Epidemiology / Natural History (6%), and Basic Science / Preclinical (3%).

Research Type	Count	% of Total
Research summaries	62	89%

Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 9:48 PM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Patient Support

Financial & Access Support (External Programs)

View all programs →

Pulmonary Arterial Hypertension Program

Premium/CopayClosedOperated by Good Days

Visit official site

Program availability and eligibility requirements are set by each foundation. Contact them directly to learn more about your options.

Are you a patient organization for this condition?

Claim this page and your organization will be listed here for patients and families to find.

Be recognized as the official organization
Get notified of new trials, FDA decisions, and research
Appear in the disease page directory
Embed this content on your website — free

Medical References

External Resources

Orphanet

European rare disease database

Orphanet:275786

GARD

Genetic and Rare Diseases Info Center

GARD:21026

Questions for Your Care Team

→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

drug- or toxin-induced pulmonary arterial hypertension

Overview

Diagnosis

Research Landscape

Patient Support

Financial & Access Support (External Programs)

Are you a patient organization for this condition?

Medical References

External Resources

Orphanet

GARD

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Recent Publications